Results 121 to 130 of about 614 (173)

Kinetics of N-acetylprocainamide deacetylation

Clinical Pharmacology and Therapeutics, 1980
The kinetics of N-acetylprocainamide (NAPA) deacetylation to procainamide (PA) were determined in a normal subject using NAPA-13C, labeled in the acetyl group. The deacetylation clearance of NAPA (ClD) was found to be 6.5 ml/min whereas total NAPA elimination clearance was 231 ml/min, so that 2.8% of the administered NAPA-13C was metabolized by ...
G P, Stec, T I, Ruo, J P, Thenot, A J, Atkinson, Y, Morita, J J, Lertora   +5 more
openaire   +2 more sources

Clinical Pharmacokinetics of N-acetylprocainamide

Clinical Pharmacokinetics, 1982
Since N-acetylprocainamide was identified in the urine of patients receiving procainamide, this compound has been studied both as a metabolite of procainamide and as a separate antiarrhythmic agent. N-acetylprocainamide absorption following oral administration is more than 8-% complete.
S J, Connolly, R E, Kates
openaire   +2 more sources

Antiarrhythmic potency of N‐acetylprocainamide

Clinical Pharmacology & Therapeutics, 1975
Compared to procainamide in an animal arrhythmia model, the antiarrhythmic potency of the N‐acetylated metabolite of procainamide (NAPA) was 92% with respect to dose and 70% with respect to plasma level. The antiarrhythmic effects of combinations of the drugs were additive.
J, Elson, J M, Strong, W K, Lee, A J, Atkinson   +3 more
openaire   +2 more sources

PHARMACOKINETICS OF N-ACETYLPROCAINAMIDE IN MAN

, 1977
John M. Strong, John S. Dutcher, Woong-Ku Lee, Arttiur J. Atkinson   +3 more
openaire   +2 more sources

Plasma Concentrations of Desethyl N-Acetylprocainamide in Patients Treated with Procainamide and N-Acetylprocainamide

Therapeutic Drug Monitoring, 1981
We describe a method for routinely measuring plasma concentrations of procainamide (PA), N-acetylprocainamide (NAPA) and desethyl N-acetylprocainamide (NAPADE) by high-performance liquid chromatography (HPLC). The method has been used together with mass spectrometry of the appropriate chromatographic fraction to demonstrate that NAPADE is a metabolite ...
T I, Ruo, J P, Thenot, G P, Stec, A J, Atkinson   +3 more
openaire   +2 more sources

Torsades de Pointes Due to N‐Acetylprocainamide

Pacing and Clinical Electrophysiology, 1985
A 66‐year‐old female with chronic renal failure received five doses of procainamide and developed marked QT interval prolongation and recurrent episodes of torsades de pointes. which were temporally related to high serum n‐acetylprocainamide (NAPA) levels and not to procainamide levels.
W G, Stevenson, J, Weiss
openaire   +2 more sources

Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide

The American Journal of Cardiology, 1981
Eleven patients with chronic ventricular arrhythmias took part in a study of N-acetylprocainamide (NAPA), the major metabolite of procainamide, in order to characterize further NAPA's clinical pharmacology and antiarrhythmic action. The frequency of ventricular arrhythmia on 24 hour ambulatory electrocardiographic recordings was comparable on ...
R A, Winkle, P, Jaillon, R E, Kates, F, Peters   +3 more
openaire   +2 more sources

N-Acetylprocainamide kinetics and clinical response during repeated dosing

Clinical Pharmacology and Therapeutics, 1982
Kinetics of and clinical responses to N-acetylprocainamide (NAPA) were evaluated in 10 patients with chronic ventricular arrhythmias who had not responded to usual doses of currently available antiarrhythmic drugs. Kinetic data analysis was by measured NAPA concentrations (n = 149) collected during repeated dosing. Response was evaluated with serial 24-
J H, Rodman, A, Hurst, T, Gaarder, J, Cohen, R W, Jelliffe   +4 more
openaire   +2 more sources

Electrophysiologic effects of N-acetylprocainamide in human beings

The American Journal of Cardiology, 1981
The electrophysiologic properties of N-acetylprocainamide (NAPA) were studied in 10 patients undergoing cardiac catheterization. Each patient received two successive intravenous infusions: one loading infusion over 15 minutes and one maintenance infusion at a slower rate for 30 minutes.
P, Jaillon, D, Rubenson, F, Peters, J W, Mason, R A, Winkle   +4 more
openaire   +2 more sources

Tissue distribution of N-acetylprocainamide in rats.

Drug Metabolism and Disposition, 1981
The purpose of this study was to determine the distribution of N-acetylprocainamide (NAPA) in heart, kidney, and liver tissues of rats and their relationship to the plasma concentration after intravenous administration of the drug (100 mg/kg) to 24 Charles River rats. A specific HPLC procedure was used.
A, Yacobi, H F, Stampfli, C M, Lai, B L, Kamath   +3 more
openaire   +2 more sources